8-K: Kenvue Q2 Sales Dip, Outlook Cut Amid Strategic Review

Kenvue Inc. reported a 4.0% decline in second-quarter net sales and revised its full-year 2025 outlook downwards, while continuing its strategic alternatives review.

Summary

• Net sales for the second quarter ended June 29, 2025, decreased 4.0% to $3,839 million compared to $4,000 million in the prior year period.
• Organic sales declined 4.2%, primarily due to 0.9% unfavorable value realization from strategic price investments and a 3.3% volume decline.
• Volume decline was impacted by sequential deceleration in category growth, weak allergy and sun seasons in North America, trade inventory fluctuations, and changes in shipment timing in China.
• Diluted earnings per share (EPS) were $0.22, up from $0.03 in the prior year, which was impacted by non-cash asset impairment charges.
• Adjusted diluted EPS decreased to $0.29 from $0.32 in the prior year period.
• Gross profit margin contracted 20 basis points to 58.9%, and Adjusted gross profit margin declined 70 basis points to 60.9%.
• Operating income margin was 18.0% compared to 3.9% in the prior year, while Adjusted operating income margin was 22.7% compared to 22.8%.
• The company revised its Full Year 2025 outlook, expecting Net sales and Organic sales to be down low-single-digits, Adjusted operating income margin to decline year-over-year, and Adjusted diluted EPS to be in the range of $1.00 to $1.05.
• The Board continues its comprehensive review of strategic alternatives to unlock shareholder value, considering options like optimizing the brand portfolio and improving operational performance.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to declining sales, reduced profitability metrics (adjusted gross profit margin, adjusted EPS), and a downward revision of the full-year outlook. While management is addressing challenges through a strategic review and new appointments, the immediate financial performance and guidance are concerning.

Positives

• Operating income margin significantly improved to 18.0% from 3.9% in the prior year period, though the prior year was impacted by non-cash asset impairment.
• Free cash flow for the six months ended June 29, 2025, increased to $0.8 billion from $0.5 billion in the prior year period.
• The company is actively focused on improving execution and performance, and advancing a comprehensive strategic alternatives review to deliver inherent value.
• New leadership appointments, including an Interim Chief Executive Officer, Chief Financial Officer, Group President, Asia Pacific, and Chief Technology & Data Officer, aim to accelerate profitable growth.

Negatives

• Net sales decreased 4.0% in the second quarter compared to the prior year period.
• Organic sales declined 4.2%, driven by unfavorable value realization and a 3.3% volume decline.
• Adjusted diluted earnings per share decreased to $0.29 from $0.32 in the prior year period.
• Adjusted gross profit margin declined 70 basis points to 60.9% due to unfavorable mix, inflationary and foreign exchange headwinds, and strategic price investments.
• The company revised its Full Year 2025 outlook downwards, expecting Net sales and Organic sales to be down low-single-digits.
• Adjusted operating income margin is expected to decline year-over-year for Full Year 2025.
• The effective tax rate increased significantly to 28.6% from 10.8% in the prior year period, largely reflecting reductions in discrete tax benefits.

Risks

• Inability to execute on Kenvue's business development strategy.
• Impact of inflation and other economic factors, such as interest rate and currency exchange rate fluctuations, as well as existing or proposed tariffs and other constraints on trade.
• Challenges in successfully managing local, regional, or global economic volatility, including reduced market growth rates.
• Ability to maintain satisfactory credit ratings and access capital markets, which could adversely affect liquidity, capital position, and borrowing costs.
• Competition, including technological advances, new products, and intellectual property attained by competitors.
• Challenges inherent in new product research and development and uncertainty of commercial success for new and existing products.
• Challenges to intellectual property protections, including counterfeiting.
• Ability to successfully execute strategic plans, including restructuring or cost-saving initiatives.
• Impact of business combinations and divestitures, including any ongoing or future transactions.
• Manufacturing difficulties or delays, internally or within the supply chain.
• Product efficacy or safety concerns resulting in product recalls or regulatory action.
• Significant adverse litigation or government action, including related to product liability claims.
• Changes to applicable laws and regulations and other requirements imposed by stakeholders.
• Changes in behavior and spending patterns of consumers.
• Natural disasters, acts of war, or terrorism, catastrophes, or epidemics, pandemics, or other disease outbreaks.
• Financial instability of international economies and legal systems and sovereign risk.
• Inability to realize the benefits of the separation from Kenvue's former parent, Johnson & Johnson.
• The risk of disruption or unanticipated costs in connection with the separation.
• The outcome and timing of the strategic review process, which may be suspended or modified at any time.
• The possibility that the Company may decide not to undertake a strategic alternative following the Board's strategic review process.
• The Company's inability to consummate any proposed strategic alternative resulting from the strategic review due to market, regulatory, and other factors.
• The potential for disruption to the Company's business resulting from the strategic review process.
• Potential adverse effects on the Company's stock price from the announcement, suspension, or consummation of the strategic review process and its results.

Future Outlook

Kenvue revised its Full Year 2025 outlook, now expecting Net sales and Organic sales to be down low-single-digits, assuming approximately neutral impact from foreign currency translation. Adjusted operating income margin is expected to decline year-over-year. Adjusted diluted earnings per share are projected to be in the range of $1.00 to $1.05, including a low-single-digit unfavorable impact from foreign currency.

Management Comments

• Kirk Perry, Interim Chief Executive Officer: "We are actively focused on improving execution and performance, while advancing the comprehensive strategic alternatives review, to deliver our inherent value."
• Kirk Perry, Interim Chief Executive Officer: "I'm thrilled to take on this new role at such an important time for the Company and am committed to ensuring we have the right talent, brand portfolio, and operational foundation in place to accelerate profitable growth and best position Kenvue to realize its full potential."
• Amit Banati, Chief Financial Officer: "We are adjusting our outlook for 2025 to reflect the year-to-date results, as well as our current expectations for the second half of the year, considering the dynamic external environment and underlying business fundamentals."
• Amit Banati, Chief Financial Officer: "While current results do not reflect the Company's full potential, I am confident that we are taking the appropriate actions to deliver sustainable value for our shareholders."

Industry Context

Kenvue's performance reflects broader challenges in the consumer health sector, including decelerating category growth and specific seasonal weaknesses (allergy and sun seasons in North America). The decline in organic sales, driven by volume and strategic price investments, suggests a competitive market where pricing power may be constrained. The ongoing strategic review indicates a proactive approach to adapt to these dynamics and unlock value, a common theme among large consumer goods companies facing evolving consumer preferences and supply chain pressures.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Face immediate negative impacts from declining sales and a lowered outlook, but may benefit from potential value creation if the strategic review yields positive outcomes.
• Employees: Subject to ongoing restructuring initiatives (Our Vue Forward) which include employee-related costs, but also benefit from new leadership appointments aimed at accelerating growth.
• Customers: May experience changes due to 'strategic price investments' and potential portfolio optimization resulting from the strategic review.
• Suppliers: Could be impacted by changes in volume demand due to sales declines and potential supply chain optimization initiatives.

Next Steps

• Kenvue will host a conference call with investors on August 7, 2025, to discuss its second quarter results.
• The company plans to update shareholders as the comprehensive strategic review progresses.
• Separation-related costs are not expected to be recorded subsequent to the fiscal third quarter of 2025.

Key Dates

Recommendation

Kenvue's Q2 2025 results show a significant decline in net sales and organic sales, coupled with a downward revision of its full-year 2025 outlook for sales, operating income margin, and adjusted EPS. The volume decline is attributed to market conditions and execution issues. While a strategic review is underway and new management is in place, the immediate financial trajectory is concerning, indicating a need for investors to consider reducing exposure until there are clear signs of operational improvement and a defined strategic path that can reverse the negative trends.

Keywords

Consumer Health, Household Products, Personal Care, Pharmaceuticals, OTC, Earnings, Financial Results, Strategic Review, Kenvue, KVUE